Elena Guerini-Rocco

List of Publications by Year
in descending order

85	2,625	218381	205818
papers	citations	26 h-index	48 g-index

86	86	86	4352
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	5.8	605
2	Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. Journal of Clinical Oncology, 2015, 33, 3945-3952.	0.8	153
3	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	3.2	119
4	Dynamic Retention of Ero1Î± and Ero1Î²2 in the Endoplasmic Reticulum by Interactions with PDI and ERp44. Antioxidants and Redox Signaling, 2006, 8, 274-282.	2.5	93
5	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2017, 12, 1654-1663.	0.5	81
6	Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions. Gynecologic Oncology, 2014, 134, 410-418.	0.6	79
7	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Modern Pathology, 2016, 29, 1292-1305.	2.9	68
8	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 2020, 11, 719.	1.0	67
9	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Frontiers in Molecular Biosciences, 2022, 9, 834651.	1.6	63
10	Eâ€cadherin deregulation in breast cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 5930-5936.	1.6	59
11	HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Modern Pathology, 2013, 26, 816-824.	2.9	57
12	Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacological Research, 2017, 117, 406-415.	3.1	55
13	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	2.1	53
14	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	1.8	53
15	Microglandular adenosis associated with tripleâ€negative breast cancer is a neoplastic lesion of tripleâ€negative phenotype harbouring <scp>TP53</scp> somatic mutations. Journal of Pathology, 2016, 238, 677-688.	2.1	52
16	The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology, 2017, 241, 405-419.	2.1	52
17	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology, 2017, 30, 69-84.	2.9	48
18	PI3K Pathway Activation in High-Grade Ductal CarcinomaIn Situâ€”Implications for Progression to Invasive Breast Carcinoma. Clinical Cancer Research, 2014, 20, 2326-2337.	3.2	41

#	Article	IF	Citations
19	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	1.6	37
20	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers, 2020, 12, 1598.	1.7	37
21	SARS-CoV-2 detection in formalin-fixed paraffin-embedded tissue specimens from surgical resection of tongue squamous cell carcinoma. Journal of Clinical Pathology, 2020, 73, 754-757.	1.0	34
22	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. BMC Cancer, 2018, 18, 935.	1.1	32
23	Understanding EGFR heterogeneity in lung cancer. ESMO Open, 2020, 5, e000919.	2.0	32
24	Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. Breast Cancer Research, 2020, 22, 107.	2.2	32
25	HotspotESR1Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Research, 2022, 82, 1321-1339.	0.4	30
26	Recurrent <scp>NAB</scp>2â€“<scp>STAT</scp>6 gene fusions and oestrogen receptorâ€Î± expression in pulmonary adenofibromas. Histopathology, 2017, 70, 906-917.	1.6	29
27	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyperÂ®. Breast Cancer Research, 2017, 19, 55.	2.2	29
28	Contrast-Enhanced Computed Tomography Colonography in Preoperative Distinction between T1-T2 and T3-T4 Staging of Colon Cancer. Academic Radiology, 2013, 20, 590-595.	1.3	26
29	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell International, 2021, 21, 266.	1.8	26
30	Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. Cancers, 2021, 13, 2172.	1.7	25
31	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 787-800.	0.9	25
32	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. Critical Reviews in Oncology/Hematology, 2022, 172, 103643.	2.0	25
33	The Oncofetal Protein IMP3: A Useful Marker to Predict Poor Clinical Outcome in Neuroendocrine Tumors of the Lung. Journal of Thoracic Oncology, 2014, 9, 1656-1661.	0.5	23
34	Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. Cancers, 2019, 11, 1641.	1.7	22
35	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the â€œProgrammed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinomaâ€• Journal of Pathology Informatics, 2021, 12, 1.	0.8	22
36	Schwann cell hamartoma: case report. BMC Gastroenterology, 2011, 11, 68.	0.8	21

#	Article	IF	Citations
37	Circulating and tissue biomarkers in early-stage non-small. Ecancermedicalscience, 2017, 11, 717.	0.6	19
38	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. Critical Reviews in Oncology/Hematology, 2018, 132, 125-129.	2.0	19
39	Wholeâ€exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology, 2019, 75, 931-937.	1.6	16
40	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. Anticancer Research, 2020, 40, 427-433.	0.5	16
41	The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. Journal of Clinical Pathology, 2018, 71, 767-773.	1.0	14
42	Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. Journal of Clinical Pathology, 2020, 73, 168-171.	1.0	14
43	A role for the immune system in advanced laryngeal cancer. Scientific Reports, 2020, 10, 18327.	1.6	14
44	The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations. PLoS ONE, 2015, 10, e0144923.	1.1	12
45	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. Cancers, 2020, 12, 1800.	1.7	12
46	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. Cells, 2021, 10, 611.	1.8	11
47	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast, 2021, 59, 94-101.	0.9	11
48	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research, 2019, 21, 153.	2.2	10
49	Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. Diagnostics, 2022, 12, 477.	1.3	10
50	The Birth of an Adenoid Cystic Carcinoma. International Journal of Surgical Pathology, 2015, 23, 26-27.	0.4	9
51	ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm. JCO Precision Oncology, 2017, 1, 1-9.	1.5	9
52	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. BMC Cancer, 2021, 21, 1152.	1.1	9
53	Successful treatment with avapritinib in patient with mucosal metastatic melanoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094615.	1.4	8
54	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Frontiers in Oncology, 2021, 11, 723693.	1.3	8

#	Article	IF	Citations
55	Rediscovering Secondary Tumors of the Prostate in the Molecular Era. Advances in Anatomic Pathology, 2016, 23, 170-179.	2.4	7
56	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. Journal of Clinical Medicine, 2019, 8, 112.	1.0	7
57	Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. Clinical Lung Cancer, 2016, 17, e179-e183.	1.1	6
58	Letter to the Editor. Clinical Lung Cancer, 2018, 19, e439-e440.	1.1	6
59	Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancerâ€"A Europe-Wide External Quality Assessment. Cancers, 2021, 13, 4718.	1.7	6
60	Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. Tumori, 2022, 108, 196-203.	0.6	6
61	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. Breast Cancer Research and Treatment, 2018, 170, 351-360.	1.1	5
62	The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy. Immunotherapy, 2018, 10, 1041-1045.	1.0	5
63	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptorâ€"positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	3.2	5
64	Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study. Jornal Brasileiro De Pneumologia, 2021, 47, e20200584.	0.4	5
65	Acquired Resistance to Tyrosine Kinase Inhibitors in Nonâ€"Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasoundâ€"Guided Transbronchial Needle Aspiration Samples. Archives of Pathology and Laboratory Medicine, 2018, 142, 465-473.	1.2	4
66	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics, 2021, 21, 757-766.	1.5	4
67	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Current Oncology, 2021, 28, 3384-3392.	0.9	4
68	Looking for sputum biomarkers in lung cancer secondary prevention: where are we now?. Journal of Thoracic Disease, 2017, 9, 4277-4279.	0.6	3
69	Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock. Translational Lung Cancer Research, 2019, 8, S360-S363.	1.3	3
70	Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. Journal of Clinical Pathology, 2020, 74, jclinpath-2020-206800.	1.0	3
71	Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies. Genes, 2020, 11, 846.	1.0	3
72	Pharmacological management of male breast cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 1493-1504.	0.9	3

#	Article	IF	Citations
73	Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC). Cancers, 2021, 13, 609.	1.7	3
74	Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Futureâ€"Five-Yearsâ€™ Single-Institution Experience of 762 Consecutive Patients. Cancers, 2022, 14, 1638.	1.7	3
75	Hibernation in Unusual Places: A Pure Typical Hibernoma of the Breast. Breast Journal, 2017, 23, 104-105.	0.4	2
76	Premalignant and Pre-invasive Lesions of the Breast. , 2017, , 103-120.		2
77	IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes. Medical Oncology, 2018, 35, 2.	1.2	1
78	Molecular profile in non-small cell lung cancers (NSCLCs) occurring in elderly.. Journal of Clinical Oncology, 2016, 34, 10053-10053.	0.8	1
79	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the â€œSOLEâ€•trial.. Journal of Clinical Oncology, 2018, 36, 517-517.	0.8	1
80	Analytical evaluation of a commercial in-house homologous recombination deficiency (HRD) assay for patients with epithelial ovarian cancers and its concordance with a reference standard.. Journal of Clinical Oncology, 2022, 40, e17592-e17592.	0.8	1
81	Histologically-Proven Efficacy of Bland Embolization in a Patient with Net Liver Metastasis. CardioVascular and Interventional Radiology, 2016, 39, 948-952.	0.9	0
82	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. Breast Cancer Research and Treatment, 2022, 191, 137-145.	1.1	0
83	Molecular biomarkers in early-stage lung cancer.. Journal of Clinical Oncology, 2016, 34, e23082-e23082.	0.8	0
84	BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy.. Journal of Clinical Oncology, 2019, 37, 5572-5572.	0.8	0
85	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. Journal of Clinical Oncology, 2020, 38, e12570-e12570.	0.8	0